Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Benchmark Downgrades Invitae to Hold

Benchmark analyst Bruce Jackson downgrades Invitae (NYSE:NVTA) from Buy to Hold.

byBenzinga Newsdesk

July 19, 2022

1 minute read

Benchmark analyst Bruce Jackson downgrades Invitae (NYSE:NVTA) from Buy to Hold.

Tabula Rasa HealthCare Q2 EPS $(0.01) Down From $0.07 YoY, Sales $82.30M Beat $81.66M Estimate

By Benzinga Newsdesk

Today, 11:06 AM

Tabula Rasa HealthCare (NASDAQ:TRHC) reported quarterly losses of $(0.01) per share. This is a 114.29 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly

TRHC

JP Morgan Downgrades Mirati Therapeutics to Neutral, Lowers Price Target to $65

By Benzinga Newsdesk

Today, 11:06 AM

JP Morgan analyst Eric Joseph downgrades Mirati Therapeutics (NASDAQ:MRTX) from Overweight to Neutral and lowers the price target from $94 to $65.

MRTX

CTI BioPharma’s COVID-19 Candidate Misses Primary Endpoint Mark In Phase 2 Trial

By Vandana Singh

Today, 11:06 AM

CTI BioPharma Corp (NASDAQ:CTIC) has announced topline results from the PRE-VENT trial of pacritinib in hospitalized COVID-19 patients. The final PRE-VENT…

CTIC

T2 Biosystems Q2 EPS $(0.08), Inline, Sales $6.70M Beat $6.12M Estimate

By Bill Haddad

Today, 11:06 AM

T2 Biosystems (NASDAQ:TTOO) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 11.11 percent increase over losses of $(0.09) per share from the same period last year. The

TTOO

Benchmark Downgrades Invitae to Hold

Related Posts

Tabula Rasa HealthCare Q2 EPS $(0.01) Down From $0.07 YoY, Sales $82.30M Beat $81.66M Estimate

JP Morgan Downgrades Mirati Therapeutics to Neutral, Lowers Price Target to $65

CTI BioPharma’s COVID-19 Candidate Misses Primary Endpoint Mark In Phase 2 Trial

T2 Biosystems Q2 EPS $(0.08), Inline, Sales $6.70M Beat $6.12M Estimate